05/05/2026
Peri-implantitis is a brain disease.
Provocative? Yes. Evidence-based? Increasingly so.
A March 2026 mini review by Cafferata and Schwarz in Frontiers in Dental Medicine consolidates the case (Cafferata & Schwarz, 2026).
The chain of evidence.
CRP is up to 3x higher in peri-implantitis patients than in healthy implant controls. IL-6 is nearly doubled. They reach the bloodstream. They reach the brain. They activate microglia. They cross perivascular spaces. They participate in the inflammatory pathways that, in longitudinal cohorts, predict accelerated cognitive decline, reduced gray matter, and reduced hippocampal volume (Kipinoinen et al., 2022; Singh-Manoux et al., 2014; Satizabal et al., 2012).
A 2025 clinical trial showed that treating peri-implantitis significantly reduces circulating CRP, LDL cholesterol, and TNF-alpha within 6 months.
The honest version of the same statement.
"Brain disease" is a deliberate reframe. The clinical category remains peri-implantitis. The mental model is what should change. The cognitive evidence is observational, not interventional. Causation has not been demonstrated by RCT. Confounders include age, frailty, socioeconomic status, oral hygiene, and multimorbidity.
And a critical clinical caveat. Up to 50 percent of peri-implant adjacent malignant lesions are initially misdiagnosed as peri-implantitis, with final histology revealing squamous cell carcinoma in up to 97 percent of cases. Persistent or atypical lesions deserve histopathology, not assumption.
The most quietly devastating finding from the review has nothing to do with biology.
89 percent of patients with peri-implantitis-affected implants believed their implants were healthy.
You cannot ask a patient to maintain something they do not know is sick.
Treat the pocket. Protect the cortex.
Cafferata EA & Schwarz F. Front Dent Med. 2026
Galarraga-Vinueza et al. J Periodontol. 2025